Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.34 - $4.04 $56,222 - $68,005
16,833 New
16,833 $59,000
Q1 2023

May 15, 2023

SELL
$3.93 - $4.69 $7,753 - $9,253
-1,973 Reduced 9.15%
19,592 $80,000
Q4 2022

Feb 14, 2023

SELL
$3.53 - $4.39 $48,551 - $60,380
-13,754 Reduced 38.94%
21,565 $94,000
Q3 2022

Nov 14, 2022

BUY
$3.26 - $4.86 $74,282 - $110,739
22,786 Added 181.81%
35,319 $129,000

Others Institutions Holding GNFT

About Genfit S.A.


  • Ticker GNFT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,815,500
  • Market Cap $274M
  • Description
  • Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...
More about GNFT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.